← Back to searchRecruitingRecruiting
Role of the Immune Environment in Response to Therapy in Breast Cancer
NCT05396612 · Abramson Cancer Center at Penn Medicine
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
About this study
This is an observational case-control study of tissues collected from women with ER+HER2- breast cancers. The immune environments of these cancers will be compared to triple negative and HER2+ breast cancers. No randomization or changes to standard of care treatment will occur as part of the study.
Eligibility criteria
Inclusion criteria:
Women 18 years of age or older with non-metastatic breast cancer undergoing surgical resection in the University of Pennsylvania Health System.
Exclusion criteria:
Males Children Pregnant individuals
Study design
Enrollment target: 300 participants
Age groups: adult, older_adult
Timeline
Starts: 2022-10-03
Estimated completion: 2032-12-31
Last updated: 2025-07-08
Interventions
Other: Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.
Primary outcomes
- • Collecting, processing and archiving breast cancer tumor tissues (Through study completion, average of 2 years)
Sponsor
Abramson Cancer Center at Penn Medicine · other
Contacts & investigators
ContactJulia T. Lewandowski · contact · Julia.Lewandowski@Pennmedicine.upenn.edu · 215-662-2861
ContactJennifer Zhang, MD · contact · Jennifer.Zhang@Pennmedicine.upenn.edu · 215-615-6810
InvestigatorJennifer Zhang, MD · principal_investigator, Abramson Cancer Center
All locations (1)
Abramson Cancer CenterRecruiting
Philadelphia, Pennsylvania, United States